Cleveland, OH, USA
A postdoctoral position is open for highly motivated candidates in the laboratory of Dr. Atul Chopra, MD, PhD, at the Harrington Discovery Institute, University Hospitals and Case Western Reserve University in Cleveland, OH. The Chopra lab discovered the fasting induced hormone asprosin that controls appetite, body weight and blood glucose levels (Cell, 2016; Nature Medicine 2017). We have identified the central asprosin receptor and characterized the anti-diabetic and anti-obesity effects of anti-asprosin monoclonal antibodies (eLife, 2021). The lab uses human genetics as an initial impetus but also specializes in biochemistry, molecular biology, cell biology, mouse genetics and physiology to enable the discovery process.
As a comprehensive, integrated, academic health system, the research enterprise at University Hospitals and Case Western Reserve University spans the full spectrum – from basic/translational to clinical research. Our lab is housed within the Harrington Discovery Institute at University Hospitals, an innovative institute for supporting drug discovery and development, and our postdoctoral scholars are supported by the vibrant CWRU research community.
To apply, please send a cover letter describing past training, interest in studying asprosin biology, a detailed CV and contact information of three referees to Dr. Chopra at email@example.com.
This search is primarily targeted towards scientists who recently completed or are in the process of completing their PhD. Start date is flexible. Researchers with a passion for the discovery process, regardless of their training background, are welcome to apply. Expertise in any of the following areas is highly valued though not required:
• Mouse (or other model organism) genetics and physiology
• Basic molecular biology and biochemistry
• Bioinformatics such as RNA-Seq, ChIP-Seq etc.
• Imaging-based cell biology techniques
Energy Regulation Mechanism and Therapeutic Potential of Asprosin.
Hoffmann JG, Xie W, Chopra AR.
Diabetes. 2020 Apr;69(4):559-566. doi: 10.2337/dbi19-0009.
Asprosin-neutralizing antibodies as a treatment for metabolic syndrome.
Mishra I, Duerrschmid C, Ku Z, He Y, Xie W, Silva ES, Hoffman J, Xin W, Zhang N, Xu Y, An Z, Chopra AR.
Elife. 2021 Apr 27;10:e63784. doi: 10.7554/eLife.63784.
Asprosin is a centrally acting orexigenic hormone.
Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, Saha PK, Lee ME, Phillips KJ, Jain M, Jia P, Zhao Z, Farias M, Wu Q, Milewicz DM, Sutton VR, Moore DD, Butte NF, Krashes MJ, Xu Y, Chopra AR.
Nat Med. 2017 Nov 6. doi: 10.1038/nm.4432. Epub ahead of print 2017 Nov 6.
Asprosin, a Fasting-Induced Glucogenic Protein Hormone.
Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B, Sarkar P, Rendon DA, Gaber MW, LeMaire SA, Coselli JS, Milewicz DM, Sutton VR, Butte NF, Moore DD, Chopra AR.
Cell. 2016 Apr 21;165(3):566-79. doi: 10.1016/j.cell.2016.02.063. Epub 2016 Apr 14.